(Q35621718)

9 August 2017

1 reference

title

Treatment of hepatitis B e antigen-negative chronic hepatitis B with lamivudine (English)

1 reference

9 August 2017

1 reference

1 reference

1 reference

1

Mario Rizzetto

1 reference

9 August 2017

Alfredo Marzano

2

1 reference

9 August 2017

Marco Lagget

series ordinal

3

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

published in

Journal of Hepatology

1 reference

9 August 2017

volume

39 Suppl 1

1 reference

9 August 2017

page(s)

S168-71

1 reference

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900311-8

7 January 2021

10.1016/S0168-8278(03)00311-8

Identifiers

DOI

1 reference

9 August 2017

1 reference